Earnings results for Phio Pharmaceuticals (NASDAQ:PHIO)
Phio Pharmaceuticals Corp. is estimated to report earnings on 11/10/2020. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.38. The reported EPS for the same quarter last year was $-4.4.
Phio Pharmaceuticals last posted its earnings results on August 12th, 2020. The reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.31. Phio Pharmaceuticals has generated ($19.33) earnings per share over the last year. Phio Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, November 10th, 2020 based off prior year’s report dates.
Analyst Opinion on Phio Pharmaceuticals (NASDAQ:PHIO)
1 Wall Street analysts have issued ratings and price targets for Phio Pharmaceuticals in the last 12 months. Their average twelve-month price target is $4.00, predicting that the stock has a possible upside of 65.98%. The high price target for PHIO is $4.00 and the low price target for PHIO is $4.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of “Buy.”
Phio Pharmaceuticals has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $4.00, Phio Pharmaceuticals has a forecasted upside of 66.0% from its current price of $2.41. Phio Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.
Dividend Strength: Phio Pharmaceuticals (NASDAQ:PHIO)
Phio Pharmaceuticals does not currently pay a dividend. Phio Pharmaceuticals does not have a long track record of dividend growth.
Insiders buying/selling: Phio Pharmaceuticals (NASDAQ:PHIO)
In the past three months, Phio Pharmaceuticals insiders have bought more of their company’s stock than they have sold. Specifically, they have bought $5,000.00 in company stock and sold $0.00 in company stock. Only 0.52% of the stock of Phio Pharmaceuticals is held by insiders. Only 2.26% of the stock of Phio Pharmaceuticals is held by institutions.
Earnings and Valuation of Phio Pharmaceuticals (NASDAQ:PHIO
Earnings for Phio Pharmaceuticals are expected to grow in the coming year, from ($2.23) to $0.29 per share. The P/E ratio of Phio Pharmaceuticals is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Phio Pharmaceuticals is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Phio Pharmaceuticals has a P/B Ratio of 0.28. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.
More latest stories: here